Aspen Pharmacare normalised earnings rise 22%, HEPS to 801.5 cents
Aspen Pharmacare reported a 22% rise in normalised earnings, with normalised headline HEPS increasing to 801.5 cents. Growth was supported by strong momentum in its commercial pharmaceuticals unit during the reporting period.